NCT02646852: A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

NCT02646852
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: 

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symtomatic untreated brain or leptomeningeal metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02646852

Comments are closed.

Up ↑